The Effect of SSRIs on the Binding of 18F-FP-CIT in Parkinson Patients: A Retrospective Case Control Study

Purpose18F-FP-CIT [18F-fluorinated N-3-fluoropropyl-2-beta-carboxymethoxy-3-beta-(4-iodophenyl) nortropane] is useful for detecting striatal dopamine transporter (DAT). Since FP-CIT shows relatively high affinities for DAT and serotonin transporter (SERT), its binding can be influenced by selective serotonin reuptake inhibitors (SSRIs). We aimed to evaluate the effect of SSRIs on the binding of 18F-FP-CIT.MethodsIn our 18F-FP-CIT positron emission tomography (PET) data pool, images of 24 drug-naive Parkinson’s disease (PD) patients (62.6 ± 10.6 years), 111 PD patients taking SSRIs [escitalopram (n = 19) and fluvoxamine (n = 20)] or clonazepam (n = 72), and 10 normal people were reviewed. PET images acquired 3 h after 18F-FP-CIT injection were analyzed by an automated method using a predefined volume of interest (VOI) set of the striatum (ST), occipital cortex (OC), raphe nuclei (RN), and cerebellar cortex (CB). The uptake ratios (URs) of each VOI to the CB were compared among the groups.ResultsThe ST/CB URs of all PD groups were significantly lower than that of normal group. When adjusted for drug severity, ST/CB URs were higher in drug-naive group but had no difference among antidepressant groups. Whereas OC/CB URs were not different among groups (p > 0.05), RN/CB URs were significantly lower in SSRI groups than in non-SSRI groups (p < 0.001) and showed similar results when adjusted for disease severity.ConclusionsPD patients taking SSRIs showed significantly decreased URs in the RN but not the OC. When adjusted for Hoehn and Yar (HY) score, ST URs were not different among antidepressant groups. This result suggests that the OC may be used as a reference region for the quantification of DAT binding in 18F-FP-CIT PET images of PD patients taking SSRIs.

[1]  W. Poewe,et al.  Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: Status and recommendations The Movement Disorder Society Task Force on rating scales for Parkinson's disease , 2004, Movement disorders : official journal of the Movement Disorder Society.

[2]  Jan Booij,et al.  Dopamine transporter imaging with [123I]FP-CIT SPECT: potential effects of drugs , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[3]  Jae Seung Kim,et al.  One-step high-radiochemical-yield synthesis of [18F]FP-CIT using a protic solvent system. , 2007, Nuclear medicine and biology.

[4]  M. Kaufman,et al.  Severe depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson's‐diseased striatum , 1991, Synapse.

[5]  J. Rinne,et al.  Striatal dopamine transporter in different disability stages of Parkinson's disease studied with [(123)I]beta-CIT SPECT. , 1995, Parkinsonism & related disorders.

[6]  F I Carroll,et al.  N‐substituted phenyltropanes as in vivo binding ligands for rapid imaging studies of the dopamine transporter , 1997, Synapse.

[7]  J. Tiihonen,et al.  Characterization of C‐11 or I‐123 Labelled β‐CIT‐FP and β‐CIT‐FE Metabolism Measured in Monkey and Human Plasma. Identification of Two Labelled Metabolites with HPLC , 1996 .

[8]  A. Takáts.  [Diagnostic criteria and differential diagnosis of Parkinson disease]. , 2003, Ideggyogyaszati szemle.

[9]  J. Booij,et al.  [123I]FP‐CIT binds to the dopamine transporter as assessed by biodistribution studies in rats and SPECT studies in MPTP‐lesioned monkeys , 1997, Synapse.

[10]  E. Wolters,et al.  Disease-related and drug-induced changes in dopamine transporter expression might undermine the reliability of imaging studies of disease progression in Parkinson's disease. , 2005, Parkinsonism & related disorders.

[11]  Jan Booij,et al.  Imaging of the dopaminergic neurotransmission system using single-photon emission tomography and positron emission tomography in patients with parkinsonism , 1999, European Journal of Nuclear Medicine.

[12]  K. Jellinger,et al.  Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. , 1973, Journal of the neurological sciences.

[13]  P. Rabins,et al.  Prevalence of anxiety disorders and anxiety subtypes in patients with Parkinson's disease , 2009, Movement disorders : official journal of the Movement Disorder Society.

[14]  L. Reneman,et al.  Validation of [123I]β-CIT SPECT to Assess Serotonin Transporters In Vivo in Humans: a Double-Blind, Placebo-Controlled, Crossover Study with the Selective Serotonin Reuptake Inhibitor Citalopram , 2005, Neuropsychopharmacology.

[15]  Sylvain Houle,et al.  Regional distribution of serotonin transporter protein in postmortem human brain: is the cerebellum a SERT-free brain region? , 2005, Nuclear medicine and biology.

[16]  V. Dhawan,et al.  Dopamine transporter imaging with fluorine-18-FPCIT and PET. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[17]  S. Papapetropoulos,et al.  Psychiatric comorbidity in a population of Parkinson's disease patients , 2006, European journal of neurology.

[18]  P. Rabins,et al.  Pharmacologic treatment of anxiety disorders in Parkinson disease. , 2013, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[19]  M. Jahanshahi,et al.  Quality of life in Parkinson's disease: The relative importance of the symptoms , 2008, Movement disorders : official journal of the Movement Disorder Society.

[20]  Eileen O. Smith,et al.  Decreased single‐photon emission computed tomographic {123I}β‐CIT striatal uptake correlates with symptom severity in parkinson's disease , 1995, Annals of neurology.

[21]  Dae Hyuk Moon,et al.  Subregional Patterns of Preferential Striatal Dopamine Transporter Loss Differ in Parkinson Disease, Progressive Supranuclear Palsy, and Multiple-System Atrophy , 2012, The Journal of Nuclear Medicine.

[22]  J. Marcusson,et al.  High affinity [3H]paroxetine binding to serotonin uptake sites in human brain tissue , 1989, Brain Research.

[23]  Christer Halldin,et al.  [18F]β-CIT-FP is superior to [11C]β-CIT-FP for quantitation of the dopamine transporter , 1997 .

[24]  J. Booij,et al.  Quantification of striatal dopamine transporters with 123I-FP-CIT SPECT is influenced by the selective serotonin reuptake inhibitor paroxetine: a double-blind, placebo-controlled, crossover study in healthy control subjects. , 2007, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[25]  Donald Grosset,et al.  Role of dopamine transporter imaging in routine clinical practice , 2003, Movement disorders : official journal of the Movement Disorder Society.

[26]  Stephen A. Williams,et al.  Changes in Human In vivo Serotonin and Dopamine Transporter Availabilities during Chronic Antidepressant Administration , 2003, Neuropsychopharmacology.

[27]  M. Kuhar,et al.  Occupancy of the serotonin transporter by fluoxetine, paroxetine, and sertraline: In vivo studies with [125i]rti‐55 , 1994, Synapse.

[28]  S. Kasper,et al.  In vivo visualization of serotonin transporters in the human brain during fluoxetine treatment , 1999, European Neuropsychopharmacology.

[29]  William J. Jagust,et al.  Automated template-based PET region of interest analyses in the aging brain , 2007, NeuroImage.

[30]  Jae Seung Kim,et al.  Effect of Animal Condition and Fluvoxamine on the Result of [18F]N-3-Fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl) Nortropane ([18F]FP-CIT) PET Study in Mice , 2012, Nuclear Medicine and Molecular Imaging.